ARQT - Arcutis Biotherapeutics GAAP EPS of -$1.89 misses by $0.01 revenue of $0.73M beats by $0.07M

• Arcutis Biotherapeutics press release ( NASDAQ: ARQT ): Q3 GAAP EPS of -$1.89 misses by $0.01 .
• Revenue of $0.73M beats by $0.07M .

• Cost of sales for the quarter ended September 30, 2022 were $0.3 million driven primarily by the amortization of a milestone payment to AstraZeneca.

• Research and development (R&D) expenses for the quarter ended September 30, 2022 were $69.7 million compared to $40.6 million for the corresponding period in 2021.

• Selling, general, and administrative (G&A) expenses for the quarter ended September 30, 2022 were $35.5 million compared to $16.5 million for the corresponding period in 2021.

• Cash, cash equivalents, restricted cash, and marketable securities were $478.2 million as of September 30, 2022, compared to $388.6 million as of December 31, 2021.

For further details see: